Portal de investigación
ESTUDIO NACIONAL, MULTICENTRICO, ABIERTO, DE TRATAMIENTO DE INDUCCION CON VELCADE Y DEXAMETASONA EN PACIENTES CON MIELOMA MULTIPLE E INSUFICIENCIA RENAL NO TRATADOS PREVIAMENTE.
Datos básicos
- Código:
- RENVEL
- Protocolo:
- RENVEL
- EUDRACT:
- 2009-010827-23
- NCT:
- Centro:
- Dotación:
- Año de incio:
- Año de finalización:
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML)
Zabaleta, Aintzane; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2023-184797. 2023
A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
Perez Miguez, Carlos; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2024-201407. 2024
A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study.
Rios-Tamayo, Rafael; (...); Mateos, Maria Victoria
Article. 10.1080/16078454.2023.2178997. 2023
A High Percentage of DNAM-1+and Low Percentage of Tactile plus NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial
Bergua Burgues, Juan Miguel; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-189676. 2023
A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study)
Vallejo C; (...); Codesido ML
Article. 10.1007/s00277-023-05602-x. 2024
A new precision medicine test to guide personalized treatments decision for acute myeloid leukemia patients.
Ballesteros, J; (...); Robles, A
Meeting Abstract. 2017
A NOVEL IN VITRO METHOD TO QUANTIFY THE PHARMACOLOGY ACTIVITY OF BISPECIFIC ANTIBODIES IN HEMATOLOGICAL SAMPLES
Primo, D; (...); Ballesteros, J
Meeting Abstract. 2017
A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
Rodríguez-Arbolí E; (...); Montesinos P
Article. 10.1002/cncr.35618. 2024
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Vives S; (...); PETHEMA Group
Article. 10.1002/cncr.33403. 2021
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients
Sanchez, MPM; (...); Montesinos, P
Article. 10.1007/s00277-021-04542-8. 2021
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
Martínez-Cuadrón D; (...); CETLAM and PETHEMA groups
Article. 10.1007/s00277-018-3229-5. 2018
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients
Martinez-Cuadron, D; (...); Spanish PETHEMA group
Article. 10.1016/j.leukres.2018.11.006. 2019
A prognostic model for survival after salvage treatment with FLAG-Ida plus /- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia
Bergua JM; (...); PETHEMA group
Article. 10.1111/bjh.14107. 2016
A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Lopez-Guillermo, Armando; (...); Tomas, Jose Francisco
Article. 10.1080/10428194.2021.1971216. 2021
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.
Berard, Emilie; (...); Recher, Christian
Article. 10.1038/s41408-022-00700-x. 2022
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Encinas, Cristina; (...); Martinez-Lopez, Joaquin
Article. 10.1038/s41408-022-00652-2. 2022
A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia
Megías-Vericat JE; (...); Aliño SF
Article. 10.1038/tpj.2015.80. 2016
A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?
Solana-Altabella A; (...); Montesinos P
Article. 10.1007/s00277-024-05891-w. 2024
Acute hemolytic reaction by anti-Wra: Case report and review of the hemovigilance database of a tertiary care hospital.
Solves, Pilar; (...); de la Rubia, Javier
Article. 10.1016/j.transci.2021.103342. 2022
Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.
Hernandez-Boluda, Juan-Carlos; (...); PETHEMA group
Article. 10.1016/j.leukres.2022.106821. 2022
ADAMTS13 RECOVERY IN ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA AFTER CAPLACIZUMAB THERAPY. THE SPANISH REGISTRY.
Mingot-Castellano, Maria Eva; (...); Pascual Izquierdo, Cristina
Article. 10.1182/blood.2023022725. 2024
Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review
Review. 10.1177/20406207211038181. 2021
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice
Stadtmauer, Edward A.; (...); ZOE-SCT Study Grp Collaborators
Article. 10.1080/21645515.2021.1953346. 2021
Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B- Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
Bar, Noffar; (...); Costa, Luciano
Meeting Abstract. 10.1182/blood-2023-180013. 2023
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
Wong, Sandy W.; (...); Costa, Luciano J.
Meeting Abstract. 10.1182/blood-2022-159009. 2022
Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial.
Puig, Noemi; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8010. 2021
Analysis of Peripheral Blood and Bone Marrow Residual Disease Dynamics during Intensive Treatment and Maintenance in Patients with Multiple Myeloma Included in the GEM12MENOS65 and GEM14MAIN Clinical Trials
Puig, Noemi; (...); Victoria Mateos, Maria
Meeting Abstract. 10.1182/blood-2023-184837. 2023
ANALYSIS OF RESIDUAL DISEASE IN PERIPHERAL BLOOD BY MEANS OF MASS SPECTROMETRY IN PATIENTS WITH MULTIPLE MYELOMA OF THE GEM 2012 MINUS65. COMPARISON WITH THE IMWG STANDARD RESPONSE AND RESIDUAL DISEASE CRITERIA
Puig, N.; (...); Mateos, M., V
Meeting Abstract. 2021
Analysis of SNP rs16754 of WT1 gene in a series of de novo acute myeloid leukemia patients.
Article. 10.1007/s00277-012-1596-x. 2012
Analysis of three salvage treatment regimens after relapsed/refractory acute myeloi leukemia (AML) (FLAG-Ida, FLAGO-IDA and PLERIFLAG)
Bergua, J; (...); Montesinos, P
Meeting Abstract. 2018
APPLICATION OF THE MASS SEQUENCING FOR THE STUDY OF MUTATIONS, REORDERINGS AND CHANGES IN GENE EXPRESSION IN THE HEMATOLOGICAL MYELOID NEOPLASIAS
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2018
APPROACH TO THE STUDY OF THE ALTERATIONS OF METABOLISM IN THE LMA
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2018
Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin
Rodriguez-Veiga, R; (...); spanish PETHEMA group
Article. 10.1007/s00277-017-3004-z. 2017
Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial
Puig, Noemi; (...); Mateis, Maria-Victoria
Meeting Abstract. 10.1182/blood-2021-151557. 2021
Autologous or allogeneic hematopoietic stem cell transplantation as front-line treatment for adult secondary acute myeloid leukemia patients: the PETHEMA registry experience.
Serrano, Josefina; (...); Montesinos, Pau
Article. 10.1016/j.jtct.2025.02.011. 2025
Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.
García-Sancho AM; (...); Caballero D
Article. 10.3324/haematol.2021.279426. 2022
Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI).
Pascual-Izquierdo C; (...); Mingot-Castellano ME
Article. 10.1002/ajh.27498. 2024
Azacitidine or Decitabine Monotherapy for the Treatment of AML: A Comparative Systematic Review and Meta-Analysis
Saiz-Rodriguez, M; (...); Montesinos, P
Meeting Abstract. 2021
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
Labrador J; (...); Montesinos P
Article. 10.3390/cancers14092342. 2022
Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial
Gonzalez-Calle, Veronica; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1182/blood-2022-162584. 2022
Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-VRd Trial
Gonzalez-Calle, Veronica; (...); Mateos, Maria-Victoria
Meeting Abstract. https://doi.org/10.1182/blood-2022-162584. 2024
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort
De la Rubia, Javier; (...); Alegre, Adrian
Meeting Abstract. 10.1182/blood-2022-158538. 2022
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.
de la Rubia, Javier; (...); Alegre, Adrian
Article. 10.3390/cancers15112964. 2023
Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura
Gomez-Segui, I, Izquierdo, CP, Comos, JD
Review. 10.1080/17474086.2021.1956898. 2021
BRAF V600E mutation in adult acute lymphoblastic leukemia.
Alonso CM; (...); Sanz Alonso MA
Letter. 10.3109/10428194.2012.733878. 2013
BUMEL vs MEL-200 prior autologous transplant for patients with newly diagnosed multiple myeloma previously treated with bortezomib, lenalidomide and dexamethasone: final results of a phase 3 trial
Lahuerta Palacios, Juan Jose; (...); Blade, Joan
Meeting Abstract. 2022
Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)
Coppo, Paul; (...); Scully, Marie
Meeting Abstract. 10.1182/blood-2023-179316. 2023
Caplacizumab Treatment in Elderly Patients with iTTP: Updated Experience from the Spanish TTP Registry
Gomez Segui, Ines; (...); De La Rubia, Javier
Meeting Abstract. 10.1182/blood-2023-180970. 2023
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.
Garces, Juan-Jose; (...); Paiva, Bruno
Article. 10.1200/JCO.21.01365. 2022
Cis-Acting Splicing-Associated Variants Can Redefine the Molecular Signature of Genes Commonly Mutated in Acute Myeloid Leukemia
Morote-Faubel, Mireya; (...); Cervera, Jose
Meeting Abstract. 10.1182/blood-2023-177571. 2023
CLINICAL APPLICATION OF THE MASSIVE SEQUENCING ADDRESSED IN ACUTE MYELOBLASTIC LEUKEMIA
Garcia, ML; (...); Gonzalez, EB
Meeting Abstract. 2017
Clinical Characteristics of Chilean Adult Patients with Acute Myeloid Leukemia (AML): Analysis within the Framework of the Epidemiological Registry of AML of the Pethema Group
Romero, Alejandra; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-163869. 2022
Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies
Askari, Elham; (...); Garcia-Sanz, Ramon
Meeting Abstract. 10.1182/blood-2023-189581. 2023
Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry (EPI-BLAS study)
Vicente, Navarro; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-190296. 2023
Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial
Puig, Noemi; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1182/blood-2022-165441. 2022
Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.
Bernal, Teresa; (...); Montesinos, Pau
Article. 10.1002/cam4.6120. 2023
Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics
Alonso, CM; (...); Barragan, E
Article. 10.1016/j.jmoldx.2018.09.009. 2019
Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML)
Colmenares, Rafael; (...); Montesinos, Pau
Meeting Abstract. 2023
CMV REACTIVATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FROM HLA-MATCHED AND HAPLOIDENTICAL DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE.
Article. 10.1016/j.jtct.2024.01.082. 2024
Common seasonal respiratory virus infections in allogeneic stem cell transplant recipients during the SARS-COV-2 pandemic.
De La Puerta R; (...); Piñana JL
Article. 10.1038/s41409-021-01319-5. 2021
COMPARATIVE STUDY OF THE CHARACTERISTICS OF THE DIAGNOSIS AND RESPONSE TO TREATMENT IN PATIENTS AGED=60 YEARS VS. <60 YEARS WITH ACQUIRED PURPLE THROMBOTIC THROMBOCYTOPENIC. RESULTS OF THE SPANISH REGISTRATION OF PTT (REPTT)
Aracil Eva, Frances; (...); Comos Javier, De la Rubia
Meeting Abstract. 2021
COMPARISON OF AZACITIDINE AND DECITABINE FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS
Saiz-Rodriguez, M.; (...); Labrador, J.
Meeting Abstract. 2020
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Sargas, Claudia; (...); Montesinos, Pau
Article. 10.1038/s41408-023-00835-5. 2023
COMPARISON OF THREE PANELS OF NGS APPLICATION IN ONCOHEMATOLOGY TO DISCARD SOMATIC AND/OR GERMINAL VARIANTS
Guzman-Gimenez, C.; (...); Such, E.
Meeting Abstract. 2021
CONCURRENT MUTATIONS IN ZRSR2 AND TET2 CAUSE SMD-COMPATIBLE ANOMALIES IN A MOUSE MODEL
Cristian, Garcia-Ruiz; (...); Alejandra, Sanjuan-Pla
Meeting Abstract. 2021
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
Boluda, Blanca; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-160136. 2022
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Martínez-Cuadrón D; (...); CETLAM and PETHEMA groups
Article. 10.1007/s00277-018-3277-x. 2018
Corrigendum to "Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study" [Leuk. Res. 92 (March) (2020) 106352].
Rodríguez-Medina C; (...); Montesinos P
Correction. 10.1016/j.leukres.2020.106388. 2020
Curative Strategy (GEM- CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd
Mateos, Maria-Victoria; (...); San-Miguel, Jesus F.
Meeting Abstract. 10.1182/blood-2021-148423. 2021
Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
Mateos, Maria-Victoria; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-159606. 2022
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.
Mateos, Maria-Victoria; (...); San-Miguel, Jesus F
Article. 10.1200/JCO.23.02771. 2024
Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping.
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Article. 10.3390/cancers15113039. 2023
Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis.
Puerta-Alcalde, Pedro; (...); Garcia-Vidal, Carolina
Article. 10.1093/mmy/myac038. 2022
Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide - an International Collaborative Study
Kayser, S; (...); Montesinos, P
Meeting Abstract. 10.1182/blood-2018-99-111768. 2018
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.
Kayser, Sabine; (...); Schlenk, Richard F.
Meeting Abstract. 10.3324/haematol.2022.281137. 2022
Characteristics and outcome of patients with core binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.
Kayser S; (...); Levis MJ
Article. 10.3324/haematol.2021.278645. 2022
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.
Martinez-Cuadron, David; (...); On Behalf Of The Pethema Group
Article. 10.3390/cancers14112817. 2022
Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort
Stahl, M; (...); Zeidan, AM
Meeting Abstract. 10.1182/blood-2018-99-112974. 2018
Chromosomal Abnormalities and Prognosis in NPM1 -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.
Angenendt, L; (...); Schliemann, C
Article. 10.1200/JCO.19.00416. 2019
Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processing.
Calleja-Panero, Jose Luis; (...); Gonzalez Calvo, Jose
Article. 10.1016/j.gastrohep.2023.05.010. 2023
CHRONOLOGICAL AGE AS A PROGNOSTIC FACTOR IN PATIENTS WITH MULTIPLE MYELOMA NEW DIAGNOSIS NOT CANDIDATED FOR TRANSPLANTATION
Martinez Elena, Meseguer; (...); Comos Javier, De la Rubia
Meeting Abstract. 2021
Chronological age as a prognostic factor in transplant-ineligible patients with newly diagnosed Multiple Myeloma
Garcia Ruiz, Raquel; (...); de la Rubia, Javier
Meeting Abstract. 2021
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
Moreau, Philippe; (...); Goldschmidt, Hartmut
Letter. 10.1038/s41408-023-00805-x. 2023
Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)
Gonzalez, Carmen; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2023-180646. 2023
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1080/17512433.2019.1573668. 2019
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (vol 11, 16867, 2021)
Lozano, Maria L.; (...); Vicente, Vicente
Article. 10.1038/s41598-021-95732-x. 2021
DEEP INTRONIC MUTATIONS IN THE RUNX1 AND FLT3 GENES PRODUCE OPENING SPLICING IN PATIENTS WITH MYELODYSPLASIC SYNDROMES
Mireia, Boluda-Navarro; (...); Jose, Cervera
Meeting Abstract. 2021
Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies
Burgos, Leire; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2021-150092. 2021
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
Burgos, Leire; (...); Paiva, Bruno
Article. 10.1200/JCO.22.01916. 2023
Depth of Response of Isatuximab (Isa) plus Carfilzomib (K) and Dexamethasone (d) in Relapsed Multiple Myeloma: IKEMA Updated Analysis
Joseph, Mikhael; (...); Meletios, A. Dimopoulos
Article. 2022
Depth of response of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma: IKEMA updated analysis
Hajek, Roman; (...); Dimopoulos, Meletios A.
Meeting Abstract. 2022
Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia
Megias-Vericat, JE; (...); Spanish PETHEMA Grp
Article. 10.4084/MJHID.2019.016. 2019
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
Suárez EU; (...); Montesinos P
Article. 10.1007/s00277-024-05840-7. 2024
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.
Solana-Altabella, Antonio; (...); Montesinos, Pau
Article. 10.1080/17512433.2023.2174523. 2023
Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.1007/s00277-020-04186-0. 2020
Editorial: Infectious diseases and hematology: diagnosis and management
Gonzalez-Lopez, Tomas Jose; (...); Di Micco, Pierpaolo
Editorial Material. 10.3389/fmed.2024.1385874. 2024
Effect of Caplacizumab in the Recovery of ADAMTS13 Level in Patients with Autoimmune Thrombotic Thrombocytopenic Purpura. Analysis from the Spanish Registry (REPTT)
Eva Mingot, Maria; (...); Del Rio Garma, Julio
Meeting Abstract. 10.1182/blood-2023-182876. 2023
Effect of CD8(+) Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies
Moscardó F; (...); Sanz GF
Article. 10.1016/j.bbmt.2014.06.038. 2014
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Peffault de Latour R; (...); Risitano AM
Article. 10.1056/NEJMoa2109965. 2022
ELTROMBOPAG ADDED TO STANDARD IMMUNOSUPPRESSION IMPROVES RESPONSE RATE IN SEVERE APLASTIC ANEMIA: RESULTS OF THE MULTICENTER PHASE III PROSPECTIVE RANDOMIZED RACE TRIAL
Risitano, A. M.; (...); de latour, R. Peffault
Meeting Abstract. 2021
ELTROMBOPAG ADDED TO STANDARD IST IS SUPERIOR TO IST ALONE AS FRONT-LINE TREATMENT FOR SEVERE APLASTIC ANEMIA: FINAL 2-YEAR ANALYSIS OF EBMT-SAAWP RACE STUDY
Risitano, Antonio Maria; (...); de Latour, Regis Peffault
Meeting Abstract. 2024
Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.
Solana-Altabella, Antonio; (...); Montesinos, Pau
Article. 10.1080/14728214.2021.2009800. 2022
Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Meeting Abstract. 10.1182/blood-2023-180691. 2023
Epidemiology of Hereditary Thrombotic Thrombocytopenic Purpura (TTP) in Spain: Preliminary Results of a Study of the Spanish TTP Registry (REPTT)
Segui, Ines Gomez; (...); Garma, Julio Del Rio
Meeting Abstract. 2024
Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
Labrador, Jorge; (...); Manuel Alonso-Dominguez, Juan
Meeting Abstract. 10.1182/blood-2022-163016. 2022
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.
Labrador, Jorge; (...); Montesinos, Pau
Article. 10.1002/cncr.35431. 2024
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.
Boluda B; (...); Montesinos P
Article. 10.1080/10428194.2021.1938031. 2021
Evolving treatment patterns and outcomes in older patients (=60 years) with AML: changing everything to change nothing?
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1038/s41375-020-01058-4. 2020
Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.1002/jca.21901. 2021
Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Ayyappan, Sabarish; (...); Prince, H. Miles
Meeting Abstract. 10.1182/blood-2023-179818. 2023
Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.
Gonzalez-Lopez, Tomas Jose; (...); Garcia-Donas Gabaldon, Gloria
Article. 10.1182/blood.2024024250. 2024
Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.
Eirís J; (...); Sanz J
Article. 10.1016/j.jtct.2024.10.009. 2024
Genomic profiling of high-risk smoldering myeloma patients treated with a curative strategy: a biological study of the phase II GEM CESAR clinical trial
Medina, Alejandro; (...); Garcia-Sanz, Ramon
Meeting Abstract. 2023
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.
de la Rubia J; (...); Bonanad, Santiago
Article. 10.1016/j.jgo.2022.10.016. 2022
GERMINAL PREDISPOSITION IN PATIENTS WITH MYELOID NEOPLASMS: ASSOCIATION BETWEEN MOLECULAR DISORDERS AND CLINICAL HISTORY
Marta, Santiago; (...); Jose, Cervera
Meeting Abstract. 2021
GERMLINE PREDISPOSITION TO MYELOID MALIGNANCIES IN A CONSECUTIVE COHORT OF 183 PATIENTS
Santiago, M.; (...); Cervera-Zamora, J.
Meeting Abstract. 10.1016/j.leukres.2023.107247. 2023
Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.
Ballesta-López O; (...); Montesinos P
Review. 10.2217/fon-2020-0700. 2020
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.
Solana-Altabella A; (...); Montesinos P
Article. 10.1111/ejh.13604. 2021
Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study
Iskierka-Jazdzewska, Elzbieta; (...); Ivanescu, Cristina
Meeting Abstract. 10.1182/blood-2023-180743. 2023
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
Rodriguez-Otero, Paula; (...); Gutierrez, Norma
Meeting Abstract. 2023
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
Gonzalez-Calle, Veronica; (...); Gutierrez, Norma C.
Article. 10.1002/hem3.70031. 2024
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
de Arriba de la Fuente, Felipe, Montes Gaisan, Carmen, de la Rubia Comos, Javier
Review. 10.3390/cancers15010155. 2023
IDIOPATHIC UPPER GASTROINTESTINAL BLEEDING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: AN UNPRECEDENTED COMPLICATION
Eiris, Juan; (...); Balaguer-Rosello, Aitana
Meeting Abstract. 2024
IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients.
Vallejo, Carlos; (...); Peman, Javier
Article. 10.3390/jof9060628. 2023
Immune biomarkers of survival and infection-related mortality in multiple myeloma (MM) patients treated with lenalidomide and dexamethasone (Rd)
Maia, Catarina; (...); Paiva, Bruno
Meeting Abstract. 2022
Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
Maia, Catarina; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-163058. 2022
Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT).
Gomez-Segui, I; (...); de la Rubia Comos, J
Article. 10.1111/bjh.19109. 2023
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.
Lakhwani S; (...); Hernández MT
Article. 10.1007/s00277-024-06031-0. 2024
Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-166826. 2022
Immunotherapy in multiple myeloma.
Asensi Cantó P, Arnao Herraiz M, de la Rubia Comos J
Article. 10.1016/j.medcli.2023.11.019. 2024
Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2016.1231405. 2017
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.
Ayala, Rosa; (...); Montesinos, Pau
Article. 10.3390/cancers14235799. 2022
Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort
Stahl, M; (...); Zeidan, AM
Meeting Abstract. 10.1182/blood-2018-99-112495. 2018
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
Paiva B; (...); PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) coop
Article. 10.1038/s41375-021-01126-3. 2021
Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1038/tpj.2017.19. 2018
Impact of natural-killer immune reconstitution on the development of cytomegalovirus infection, non-relapse mortality, and graft versus host disease after allogeneic stem cell transplantation
Rodriguez-Veiga, R.; (...); Sanz, M. A.
Meeting Abstract. 2015
Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1097/FPC.0000000000000286. 2017
IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.
Marco-Ayala, Javier; (...); Solves, Pilar
Article. 10.1016/j.jtct.2023.01.009. 2023
Impact of t(11;14) according to induction regimen in newly diagnosed transplant-eligible multiple myeloma patients: long term follow-up of GEM05MENOS65 and GEM2012 PETHEMA/GEM studies
Moreno, David; (...); Rosinol, Laura
Meeting Abstract. 2021
Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia
Barba P; (...); Ribera JM
Article. 10.3109/10428194.2015.1014365. 2015
Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Meeting Abstract. 2015
Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia.
Kayser, Sabine; (...); Schlenk, Richard F.
Article. 10.3324/haematol.2022.282127. 2023
Improved outcomes in allo-HCT for multiple myeloma patients with thiotepa-busulfan-fludarabine conditioning regimen and post-transplant cyclophosphamide, sirolimus and mycophenolate mofetil
de la Rubia, Javier; (...); Sanz, Miguel
Meeting Abstract. 2023
Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.
Onecha E; (...); Ayala R
Article. 10.1111/bjh.16432. 2020
Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
Rodríguez-Veiga R; (...); Sanz GF
Article. 10.1007/s00277-019-03744-5. 2019
Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.3390/cancers15082267. 2023
Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis
Montesinos P; (...); Sanz MA
Article. 10.1038/bmt.2015.181. 2015
Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.
Asensi Cantó P; (...); Sanz J
Article. 10.1038/s41409-024-02391-3. 2024
Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients
Pinana JL; (...); Sanz MA
Article. 10.1007/s00277-013-1872-4. 2014
Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2024.12.006. 2024
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
Sobas, Marta; (...); Montesinos, Pau
Article. 10.1007/s00277-023-05582-y. 2023
Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
Labrador, Jorge; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-162591. 2022
Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2017.1323267. 2017
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1097/FPC.0000000000000431. 2021
Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Meeting Abstract. 2015
Infusion of Haploidentical Stem Cell after Consolidation in Younger Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase I-II Study
Boluda, Blanca; (...); Sanz, Miguel A.
Meeting Abstract. 10.1182/blood.V128.22.1614.1614. 2016
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.
Simoes C; (...); Paiva B
Article. 10.1182/bloodadvances.2022008141. 2023
INTENSIVE CHEMOTHERAPY VERSUS DECITABINE FIRST LINE LAM OVER 60 YEARS OLD
De la Fuente, A.; (...); Montesinos, P.
Meeting Abstract. 2019
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.
Hajek, Roman; (...); Dimopoulos, Meletios A.
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8034. 2021
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
Dimopoulos, Meletios A.; (...); Hajek, Roman
Article. 10.1002/ajh.26602. 2022
Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial
Puig, Noemi; (...); Victoria Mateos, Maria
Meeting Abstract. 10.1182/blood-2023-182964. 2023
ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results
Ghobrial, Irene; (...); Mateos, Maria-Victoria
Meeting Abstract. 2021
Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial
Rosinol, Laura; (...); Blade Creixenti, Joan
Meeting Abstract. 10.1182/blood-2021-146798. 2021
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Rosinol, Laura; (...); Blade, Joan
Article. 10.1182/blood.2022019531. 2023
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.
Martin Garcia-Sancho, A.; (...); Caballero, D.
Article. 10.1111/bjh.18989. 2023
Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience.
Sanz, Miguel Angel; (...); Sanz, Jaime
Article. 10.1038/s41409-024-02319-x. 2024
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy
Martínez-Cuadrón D; (...); Sanz MA
Article. 10.1038/leu.2017.178. 2018
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study
Rodriguez-Arboli, E; (...); GETH Grp Espanol Trasplante Hemato
Article. 10.1016/j.jtct.2020.12.029. 2021
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.
Recher, Christian; (...); Montesinos, Pau
Article. 10.1038/s41375-021-01425-9. 2022
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.
Stahl M; (...); Zeidan AM
Article. 10.1038/s41375-020-0783-3. 2020
MASS SEQUENCING DIRECTED TO THE STUDY OF REARRANGEMENTS AND CHANGES IN GENIC EXPRESSION IN ACUTE MYELOID LEUKEMIA
Sargas Simarro, C.; (...); Barragan Gonzalez, E.
Meeting Abstract. 2019
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.
Puig, Noemi; (...); Mateos, Maria-Victoria
Article. 10.1182/bloodadvances.2021006762. 2022
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.
Simoes C; (...); Montesinos P
Article. 10.1182/bloodadvances.2020003195. 2021
MODELING OF IDH2 GENE MUTATIONS IN THE CAENORHABDITIS ELEGANS ORGANISM. DEVELOPMENT OF A NEW STUDY MODEL
Gonzalez-Romero, E.; (...); Cervera-Zamora, J.
Meeting Abstract. 2021
MOLECULAR APPROACH TO CHRONIC LYMPHOPROLIFERATIVE SYNDROMES IN THE DAILY CLINICAL PRACTICE OF A SINGLE CENTER
Mariam, Ibanez; (...); Irene, Luna
Meeting Abstract. 2021
MOLECULAR CHARACTERIZATION OF MULTIPLE MYELOMA PATIENTS BY USING A SINGLE ENRICHMENT PANEL IDENTIFYING SNVS, INDELS, CNVS AND TRANSLOCATIONS
Juan Manuel, Rosa-Rosa; (...); Joaquin, Martinez-Lopez
Meeting Abstract. 2021
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.
Sargas, Claudia; (...); On Behalf Of Pethema Group
Article. 10.3390/cancers15020438. 2023
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project.
Sargas C; (...); Montesinos P
Article. 10.3324/haematol.2020.263806. 2021
NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CALCINEURIN-FREE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS
Balaguer Rosello, Aitana; (...); Sanz, Jaime
Meeting Abstract. 2023
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
NEW MODEL TO QUANTIFY THE IN VITRO PHARMACOLOGICAL ACTIVITY OF BI-SPECIFIC ANTIBODIES IN HAEMATOLOGIC MALIGNANCIES
Primo, D.; (...); Ballesteros, J.
Meeting Abstract. 2017
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial.
Rosa-Rosa, Juan Manuel; (...); Martinez-Lopez, Joaquin
Article. 10.3390/cancers14205169. 2022
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.
Castano-Bonilla, Tamara; (...); Montesinos, Pau
Article. 10.1155/2022/3132941. 2022
OBSERVATIONAL CLINICAL TRIAL FOR THE VALIDATION OF A TEST OF PRECISION MEDICINE IN ACUTE MYELOID LEUKEMIA
Montesinos, P.; (...); Sanz, M.
Meeting Abstract. 2017
Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Kim, Won-Seog; (...); Walewski, Jan
Meeting Abstract. 10.1182/blood-2022-158406. 2022
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial
Cabrero M; (...); Caballero D
Article. 10.1038/s41409-023-02171-5. 2024
Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience.
Sobas M; (...); Giebel S
Article. 10.1016/j.clml.2019.09.616. 2020
Outcome of older (=70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.
Kayser S; (...); Montesinos P
Article. 10.1038/s41375-020-0758-4. 2020
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry
Martinez-Cuadron, David; (...); Montesinos, Pau
Article. 10.3324/haematol.2022.282506. 2024
Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database
Shallis, RM; (...); Zeidan, AM
Meeting Abstract. 10.1182/blood-2018-99-119755. 2018
P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results (vol 21, pg S109, 2021)
Ghobrial, Irene M.; (...); Mateos, Maria-Victoria
Correction. 10.1016/j.clml.2022.03.011. 2022
Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients
Ibanez, Mariam; (...); Luna I
Article. 10.3390/diagnostics12040953. 2022
Paradoxical Findings in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors: Suboptimal Disease Control Perceived As Satisfactory
Gaya, Anna; (...); Vallejo, Carlos
Meeting Abstract. 10.1182/blood-2023-185939. 2023
Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study
Rodriguez-Medina, C; (...); Fernandez, PM
Article. 10.1016/j.leukres.2020.106352. 2020
Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
Sargas, Claudia; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-166639. 2022
Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.2174/1389200218666171101124931. 2018
Pharmacogenomics and the treatment of acute myeloid leukemia
Megías-Vericat JE; (...); Aliño SF
Review. 10.2217/pgs-2016-0055. 2016
Pharmacologic evaluation of bispecific antibodies: A novel method to quantify their in vitro activity in hematologic samples.
Primo, D; (...); Ballesteros, J
Meeting Abstract. 2017
Pharmacological Profiles of Acute Myeloid Leukemia Treatments in Patient Samples by Automated Flow Cytometry: A Bridge to Individualized Medicine
Bennett TA; (...); Ballesteros J
Article. 10.1016/j.clml.2013.11.006. 2014
Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia
Martínez-Cuadrón D; (...); Sanz MA
Article. 10.1007/s00277-013-1914-y. 2014
PLZF-RAR(alpha), NPM1-RAR(alpha), and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review
Sobas, M; (...); Montesinos, P
Review. 10.3390/cancers12051313. 2020
Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
Lazzari, Lorenzo; (...); Sanz, Jaime
Article. 10.1038/s41409-022-01725-3. 2022
Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1007/s40261-019-00881-7. 2020
Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?
Megías-Vericat JE; (...); Montesinos P
Review. 10.1080/17474086.2020.1818559. 2020
Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments
Ballesteros, J; (...); Montesinos, P
Meeting Abstract. 10.1182/blood-2018-99-115849. 2018
Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment.
Minguela, Alfredo; (...); Periago, Adela
Article. 2021
Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.
Gonzalez-Lopez, Tomas Jose; (...); Fernandez-Fuertes, Fernando
Article. 10.1016/j.blre.2023.101112. 2023
Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Article. 2014
Prognostic Impact of Cytarabine Pathway Gene Polymorphisms in Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Article. 2014
Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
Uriel Suarez, Edwin; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-167365. 2022
PROGNOSTIC IMPACT OF TRANSPORTER GENE POLYMORPHISMS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA ADULTS
Megias Vericat, J. E.; (...); Sanz, M. A.
Article. 2015
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.
Castaño-Bonilla T; (...); Montesinos, P
Article. 10.1038/s41598-021-00050-x. 2021
PROGNOSTIC VALUE OF B-MYB AND ITS REGULATION BY MIRNAS IN ACUTE MYELOID LEUKEMIA
LLop, M.; (...); Angel Sanz, M.
Article. 2013
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.
Tamariz-Amador, Luis-Esteban; (...); Troconiz, Inaki F.
Article. 10.1016/j.clml.2022.04.024. 2022
PROPOSED MOLECULAR CLASSIFICATION OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BASED ON SPLICING EVENTS
Liquori, A.; (...); Cervera Zamora, J.
Meeting Abstract. 2021
Púrpura trombocitopénica trombótica inmune: sospecha y manejo básico en los servicios de urgencias. Revisión y consenso de un grupo de expertos de las sociedades científicas SEHH y SEMES.
Pascual-Izquierdo, Cristina; (...); de la Rubia Comos, Javier
Article. 10.55633/s3me/E099.2023. 2023
QUANTIFICATION OF CIRCULATING TUMOR CELLS IS THE MOST RELEVANT PROGNOSTIC FACTOR AT DIAGNOSIS IN PATIENTS WITH MULTIPLE MYELOMA, WHO ARE TRANSPLANT CANDIDATES, Abstracts
Juan-Jose, Garces; (...); Bruno, Paiva
Meeting Abstract. 2021
Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting.
Ibáñez M; (...); Sanz MA
Article. 10.1016/j.jmoldx.2012.06.006. 2012
Real life outcomes of patients aged =75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.
Salamero O; (...); PETHEMA and PALG Groups
Article. 10.1080/10428194.2019.1607327. 2019
Real world evaluation of teclistamab in patients with RRMM: results from the IMF immunotherapy database project
Costa, Luciano; (...); Wong, Sandy
Meeting Abstract. 2023
Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus.
Gonzalez-Lopez, Tomas Jose; (...); Jarque, Isidro
Article. 10.1080/09537104.2024.2336104. 2024
Real-Life Evidence of Treatment with Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Saiz-Rodriguez, M; (...); Pethema Grp
Meeting Abstract. 2021
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
Abrisqueta, Pau; (...); Villanueva, Miguel
Article. 10.1016/j.clml.2021.07.022. 2021
Real-world effectiveness of caplacizumab vs standard of care in immune thrombotic thrombocytopenic purpura.
Pascual Izquierdo, Maria Cristina; (...); Del Rio-Garma, Julio
Article. 10.1182/bloodadvances.2022008028. 2022
Real-World Experience in Extracorporeal photopheresisfor adults with graft-versus-host disease.
Asensi Cantó P; (...); Gómez-Seguí I
Article. 10.1016/j.jtct.2023.09.001. 2023
Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI).
Mingot-Castellano, Maria Eva; (...); Pascual-Izquierdo, Cristina
Article. 10.3390/jcm12206422. 2023
Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura.
Mingot Castellano, Maria Eva; (...); Grp Espanol Aferesis GEA
Practice Guideline. 10.1016/j.medcli.2021.03.040. 2022
Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part I: update on laboratory tests for the study of monoclonal gammopathies.
Cardenas, Maria C.; (...); Cruz-Iglesias, Elena
Article. 10.1515/cclm-2023-0326. 2023
Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part II: methodological and clinical recommendations for the diagnosis and follow-up of monoclonal gammopathies
Cardenas, Maria C.; (...); Cruz-Iglesias, Elena
Article. 10.1515/cclm-2023-0325. 2023
Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-167247. 2022
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Lakhwani S; (...); Hernández MT
Article. 10.3324/haematol.2023.284154. 2024
Reduced incidence of neurologic complications after allogeneic hematopoietic stem cell transplantation with calcineurin-free graft-versus-host disease prophylaxis.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.07.008. 2023
Relevancia de la anfotericina B liposomal en el tratamiento de las infecciones fúngicas invasoras en pacientes oncohematológicos.
García-Vidal C, Vázquez L, Jarque I
Article. 10.1016/j.riam.2021.03.001. 2021
Renal response to rescue treatments in Relapsed Refractory Multiple Myeloma (RRMM) patients with renal impairment: final data of a large, observational, prospective study (MIR50)
Garcia-Guinon, Antonio; (...); de la Rubia, Javier
Meeting Abstract. 2021
Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial
Paiva, B; (...); Montesinos, P
Meeting Abstract. 10.1182/blood-2018-99-113299. 2018
Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1007/s00277-018-3304-y. 2018
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups
Vives, Susana; (...); PETHEMA Grp
Article. 10.3390/cancers16234028. 2024
Secondary Acute Myeloid Leukemia from a Previous Chronic Myeloproliferative Neoplasm: A Study of Grelam-Chile Concerning Chilean Patients on Behalf of AML Pethema Registry
Espinoza, Marcela; (...); Martinez-Cuadron, David
Meeting Abstract. 10.1182/blood-2023-185288. 2023
Selective IgA Deficiency and Blood Component Transfusion: In Search of the Lost Evidence
Solves, Pilar; (...); de la Rubia, Javier
Article. 10.3390/hemato5020009. 2024
SEQUENCING OF THE EXOME IN THE RECALLING OR REFRACTORY AML
Simarro Claudia, Sargas; (...); Eva, Barragan
Meeting Abstract. 2021
Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic
Martinez-Lopez, Joaquin; (...); San-Miguel, Jesus F.
Meeting Abstract. 10.1182/blood-2021-149192. 2021
Sex differences in aortic prognosis in Marfan patients, a retrospective longitudinal study from the REPAG registry
Tura, G. Teixido; (...); Cabrera, F.
Meeting Abstract. 10.1093/eurheartj/ehae666.2264. 2024
Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons.
Seguí IG; (...); de la Rubia J
Article. 10.1080/17474086.2024.2318347. 2024
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics: a retrospective study of the PETHEMA/Spanish Myeloma Group (GEM)
Villalba, Ana; (...); De la Rubia, Javier
Meeting Abstract. 2022
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial.
Puig N; (...); Mateos MV
Article. 10.3324/haematol.2024.285742. 2024
Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease
Lakhwani, Sunil; (...); Teodoro Hernandez Garcia, Miguel
Meeting Abstract. 10.1182/blood-2023-179452. 2023
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.
Martín-Sánchez E; (...); Zabaleta A
Article. 10.1182/bloodadvances.2024013212. 2024
T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.01.016. 2023
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Medina-Herrera A; (...); Garcia-Sanz R
Article. 10.1038/s41408-024-01053-3. 2024
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial
Ayala, R; (...); Montesinos, P
Article. 10.3390/cancers13102458. 2021
The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies
Strebel, Johanna A. Kremer Hovinga; (...); Scully, Marie
Meeting Abstract. 10.1182/blood-2022-156306. 2022
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients.
Villar, Sara; (...); Montesinos, Pau
Article. 10.3389/fonc.2022.1054458. 2022
Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain
Boluda, B; (...); Montesinos, P
Article. 10.1007/s41669-018-0098-8. 2019
Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
Patricia Simoes, Catia; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-163159. 2022
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Simoes, Catia; (...); Montesinos, Pau
Letter. 10.1111/bjh.18815. 2023
Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.
Solves, Pilar; (...); Sanz, Jaime
Article. 10.3390/jcm12103467. 2023
Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment
Montesinos P; (...); Sanz MÁ
Article. 10.1016/j.riam.2014.10.003. 2015
Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry
Martinez-Cuadron, David; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-189800. 2023
Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.
Lloret-Madrid, Pilar; (...); Montesinos, Pau
Article. 10.1002/cncr.35696. 2025
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1182/bloodadvances.2021005335. 2022
Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
Megías-Vericat JE; (...); Montesinos P
Review. 10.1016/j.blre.2020.100675. 2020
Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis.
Saiz-Rodriguez, M; (...); Montesinos, P
Article. 10.3390/cancers13225677. 2021
Use of optical genome mapping in the cytogenetic diagnosis of multiple myeloma
de la Rubia, Javier; (...); Such, Esperanza
Meeting Abstract. 2023
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
Labrador J; (...); Montesinos P
Article. 10.3390/cancers14071734. 2022
Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients
Rodriguez-Veiga, Rebeca; (...); Sanz, Miguel A.
Article. 10.1111/myc.12891. 2019
Validation of a risk score for post-engraftment invasive fungal disease in 414 adult allogeneic hematopoietic stem cell transplant recipients
Montesinos, P.; (...); Sanz, M. A.
Meeting Abstract. 2016
VALIDATION OF FREQUENT SPLICING EVENTS IN ACUTE MYELOID LEUKEMIA WITH POTENTIAL TO GENERATE NEOANTIGENS
Beatriz, Fernandez-Blanco; (...); Jose Vicente, Cervera Zamora
Meeting Abstract. 2021
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.
De la Torre EP; (...); Montesinos P
Letter. 10.3324/haematol.2023.284601. 2024
VALIDATION OF PRECISION MEDICINE TEST FOR ACUTE MYELOID LEUKEMIA IN AN OBSERVATIONAL CLINICAL TRIAL
Montesinos, P; (...); Sanz, MA
Meeting Abstract. 2017
Validation of the IMWG standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?
Jimenez Ubieto, Ana; (...); Lahuerta, Juan-Jose
Article. 10.1182/blood.2021012319. 2021
WHOLE GENE SEQUENCING FOR THE IDENTIFICATION OF SPLICING MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
Mireya, Morote-Faubel; (...); Jose, Cervera
Meeting Abstract. 2021
WT1 isoform expression pattern in acute myeloid leukemia.
Article. 10.1016/j.leukres.2013.10.009. 2013